GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Additional Paid-In Capital

Chimeric Therapeutics (ASX:CHM) Additional Paid-In Capital : A$0.00 Mil(As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Additional Paid-In Capital?



Chimeric Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Chimeric Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Additional Paid-In Capital Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Additional Paid-In Capital
- - -

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial - - - - -

Chimeric Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Chimeric Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimeric Therapeutics (ASX:CHM) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines